Breast cancer: a new treatment avenue identified at the CRCHUM and the Peter MacCallum Cancer Centre

MONTREAL, May 17 /CNW Telbec/ - Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells. Over the past few years Herceptin® (trastuzumab) has become the standard treatment for this kind of cancer. While it is known that it blocks the activity of this protein, its exact mechanism of action has remained a mystery.

Professor John Stagg, a CRCHUM researcher, Professor Mark J. Smyth, with the Peter MacCallum Cancer Centre in Australia, and their colleagues* have discovered that in addition to blocking cell proliferation, Herceptin also stimulates the production of interferons, which in turn activate immune cells called lymphocytes.

For a full version of the press release: www.chumtl.qc.ca/presse.fr.html

SOURCE CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

For further information:

For more information and to obtain a copy of the study:
Lucie Dufresne
Communication Officer
Centre hospitalier de l'Université de Montréal
+ 1 514-890-8000, extension 15380
Pager: + 1 514-860-7110
lucie.dufresne.chum@ssss.gouv.qc.ca

Profil de l'entreprise

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.